Last reviewed 2026-04-23 · How we verify

Generic Ingenol Mebutate

Ingenol mebutate is a protein kinase C activator that induces rapid necrosis of treated cells and promotes immune-mediated destruction of remaining lesions.

Ingenol mebutate is a protein kinase C activator that induces rapid necrosis of treated cells and promotes immune-mediated destruction of remaining lesions. Used for Actinic keratosis.

At a glance

Mechanism of action

Ingenol mebutate activates protein kinase C (PKC), leading to direct cytotoxic effects on actinic keratosis cells through necrosis. Additionally, it triggers an immune response that eliminates residual diseased cells in the treated area. This dual mechanism—direct cell death plus immune activation—makes it effective for topical treatment of actinic keratosis.

Approved indications

• Actinic keratosis

Common side effects

• Application site erythema
• Application site pain
• Application site pruritus
• Application site edema

Key clinical trials

• A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis (PHASE3)
• An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Generic Ingenol Mebutate CI brief — competitive landscape report
• Generic Ingenol Mebutate updates RSS · CI watch RSS
• Actavis Inc. portfolio CI